Paper28612401
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
Abdel Raheem A and 9 others. BJU Int, 2017. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. Papers, record 28612401. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28612401
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Microbial Collagenase | Major topic |
| Penile Induration | Major topic |
| Adult | |
| Aged | |
| Humans | |
| Injections, Intralesional | |
| Male | |
| Middle Aged | |
| Penis | |
| Prospective Studies | |
| Treatment Outcome |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 29144915 | Re: Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease Using a New Modified Shortened Protocol. | https://conductscience.org/library/papers/29144915 |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41971130 | Current status of non-surgical treatments for Peyronie's disease. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/41971130 | PubMed |
| 41821908 | A novel approach to Peyronie's disease: Intralesional injection of lyophilized platelet-derived growth factors. | Cent European J Urol | 2026 | https://conductscience.org/library/papers/41821908 | PubMed |
| 41777620 | Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review. | Res Rep Urol | 2026 | https://conductscience.org/library/papers/41777620 | PubMed |
| 41407896 | Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation. | Int J Impot Res | 2025 | https://conductscience.org/library/papers/41407896 | PubMed |
| 40358122 | Editorial comment on "Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil". | Asian J Androl | 2025 | https://conductscience.org/library/papers/40358122 | PubMed |
| 40314553 | Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil. | Asian J Androl | 2025 | https://conductscience.org/library/papers/40314553 | PubMed |
| 39450208 | A review of Peyronie's disease insurance coverage. | Sex Med | 2024 | https://conductscience.org/library/papers/39450208 | PubMed |
| 37550385 | Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie's disease in the outpatient setting: a pilot study. | Int J Impot Res | 2024 | https://conductscience.org/library/papers/37550385 | PubMed |
| 36756281 | Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities. | Res Rep Urol | 2023 | https://conductscience.org/library/papers/36756281 | PubMed |
| 36569498 | Improvement in the ability to have sex in patients with Peyronie's disease treated with Collagenase Clostridium histolyticum. | BJUI Compass | 2023 | https://conductscience.org/library/papers/36569498 | PubMed |
| 36303674 | Global Perspective on the Management of Peyronie's Disease. | Front Reprod Health | 2022 | https://conductscience.org/library/papers/36303674 | PubMed |
| 36068002 | Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates. | Investig Clin Urol | 2022 | https://conductscience.org/library/papers/36068002 | PubMed |
| 34552787 | Peyronie's disease - outcomes of collagenase clostridium histolyticum injection: A systematic review. | Arab J Urol | 2021 | https://conductscience.org/library/papers/34552787 | PubMed |
| 33471204 | The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy. | Curr Urol Rep | 2021 | https://conductscience.org/library/papers/33471204 | PubMed |
| 33420664 | Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature. | Curr Urol Rep | 2021 | https://conductscience.org/library/papers/33420664 | PubMed |
| 33420247 | Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie's disease in a multicenter clinical study. | Sci Rep | 2021 | https://conductscience.org/library/papers/33420247 | PubMed |
| 32518629 | Recent advances in managing Peyronie's disease. | F1000Res | 2020 | https://conductscience.org/library/papers/32518629 | PubMed |
| 32366987 | Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study. | Int J Impot Res | 2021 | https://conductscience.org/library/papers/32366987 | PubMed |
| 32317742 | About the drawback of collagenase. | Int J Impot Res | 2021 | https://conductscience.org/library/papers/32317742 | PubMed |
| 32257868 | Minimally invasive therapies for Peyronie's disease: the current state of the art. | Transl Androl Urol | 2020 | https://conductscience.org/library/papers/32257868 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28612401
GET https://conductscience.org/api/papers/v1/28612401/cited_by?page=2